Empowering people, informing care decisions February 2026 ©2026 Castle Biosciences 1 Disclaimers Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning: our positioning for continued grow ...

Summary of Voyager Therapeutics FY Conference Call Company Overview - **Company**: Voyager Therapeutics (NasdaqGS: VYGR) - **Industry**: Biotechnology, specifically focusing on gene therapy and treatments for neurodegenerative diseases, particularly Alzheimer's disease Key Points 1. Strategic Focus Areas - **Three Pillars of Value**: - **Tau Target**: Focus on tau as a target for Alzheimer's with two programs: VY7523 (anti-tau antibody) and VY-1706 (gene therapy) [2][3] - **Gene Therapy**: Plans to advance two gene therapy assets into clinical trials, one in partnership with Neurocrine and one wholly owned by Voyager [2] - **NeuroShuttle Platform**: Development of a platform to deliver various drugs across the blood-brain barrier [3] 2. Tau as a Target for Alzheimer's - **Importance of Tau**: The spread of tau in the brain correlates more closely with clinical decline in Alzheimer's than amyloid accumulation [6] - **Recent Developments**: Upcoming data from J&J and Biogen on tau-targeting therapies will provide further validation for tau as a target [5][6] - **Mixed Results from Competitors**: UCB's bepranemab showed some effect on tau spread but failed to meet primary clinical endpoints, indicating the complexity of targeting tau [8][9] 3. Clinical Development Insights - **VY7523**: Preliminary safety data shows a favorable profile, with a brain-to-plasma ratio of 0.3% and a half-life supporting monthly dosing [20] - **MAD Study Design**: The multiple ascending dose (MAD) study is designed to assess the effect on tau PET imaging, which is the key biomarker for evaluating the spread of pathological tau [21] - **Future Studies**: Plans to include tau PET imaging data in future studies and emphasize its importance over fluid-based biomarkers [24][25] 4. Gene Therapy Developments - **VY-1706**: Aiming for a 50%-70% reduction in tau mRNA/protein, with a focus on lower doses to enhance safety and reduce costs [31] - **FDA Interactions**: Productive discussions with the FDA regarding trial designs and plans to file an IND in Q2 2026 [33] 5. NeuroShuttle Platform - **Differentiation**: The ALPL shuttle shows longer half-life and no adverse effects on reticulocyte counts compared to transferrin receptor shuttles, making it a promising delivery method for various therapies [46] - **Therapeutic Modalities**: Exploring antibodies, peptides, and oligonucleotides for use with the NeuroShuttle platform [47] 6. Partnerships and Collaborations - **Neurocrine Partnership**: Progress on gene therapy programs, including FA and GBA1, with plans to enter the clinic this year [48] 7. Market Opportunities - **Alzheimer's Disease**: The potential for anti-tau therapies to be used in combination with anti-amyloid treatments, especially for patients who do not respond to the latter [41] - **Broader Applications**: Potential to address other tauopathies beyond Alzheimer's, expanding the market opportunities for Voyager's therapies [42] Additional Insights - **Clinical Predictions**: Anticipation that BIIB080 will show significant effects in clinical measures, which could influence Voyager's approach to VY-1706 [36] - **Patient Population**: Targeting early Alzheimer's patients for clinical trials, aligning with trends in the amyloid treatment landscape [26][27] This summary encapsulates the key discussions and insights from the Voyager Therapeutics FY Conference, highlighting the company's strategic focus, clinical developments, and market opportunities in the biotechnology sector.

Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. Topline results showed TX45 was well tolerated and improved both left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEFTX2100 advanced into Phase 1a healthy volunteer clinical trial, randomizing the first subject in February 2026, as a potential treatment for Hereditary He ...

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year ...

Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 ...

Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO TAT on March 16, 2026 Approximately $555 million in cash, cash equivalents and investments at end of Q4 2025 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rela ...

— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. “2025 was a year of disciplined execution for P ...

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company’s common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares. “In 2025, we were able to retur ...

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care ConferenceDate: 03/04/26 Barclays 28th Annual Global Healthcare ConferenceDate: 03/10/26 Leerink Partners Global Healthcare Conference 2026Date: 03/11/26 Intereste ...

Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary data presented at 2026 WORLDSymposium™, supporting plans to pursue an accelerated approval path in Sanfilippo syndrome type AStart-up activities underway for DNL628 (OTV:MAPT) Phase 1b study for Alzheimer's disease and DNL952 (ETV:GAA) Phase 1 study for late-onset Pompe diseaseTransportVehicle™ platform an ...